Court Opinion

ID: 9906386
Source: CourtListenerOpinion
Date Created: 2023-12-01 21:02:40.033959+00
Date Added: 2024-06-11T09:24:18.622806
License: Public Domain

IN THE COURT OF CHANCERY OF THE STATE OF DELAWARE

GLOBAL DISCOVERY                         )
BIOSCIENCES CORPORATION                  )
                                         )
                 Plaintiff,              )
                                         )
      v.                                 ) C.A. No. 2022-1132-SG
                                         )
DOUGLAS S. HARRINGTON, THE               )
ARK PARTNER LLC, SMART                   )
HEALTH DIAGNOSTICS COMPANY               )
F/K/A PREDICTIVE HEALTH                  )
DIAGNOSTICS COMPANY,                     )
MATTHEW NUÑEZ, DANIEL                    )
ANGRESS, and VISIONARY                   )
PRIVATE EQUITY GROUP,                    )

                  Defendants.

                        MEMORANDUM OPINION

                       Date Submitted: August 23, 2023
                       Date Decided: December 1, 2023

Stephen C. Norman, David A. Seal, Callan R. Jackson, and Charles R. Hallinan,
POTTER ANDERSON, Wilmington, Delaware; OF COUNSEL: Eric Landau and
Travis Biffar, ELLENOFF GROSSMAN & SCHOLE LLP, Irvine, California,
Attorneys for Plaintiff Global Discovery Biosciences Corporation.

Andrew L. Cole and Jack M. Dougherty, COLE SCHOTZ P.C., Wilmington,
Delaware, Attorneys for Defendant ARK Partner LLC.

Alan D. Albert, O’HAGAN MEYER, PLLC, Wilmington, Delaware, Attorney for
Defendants Douglas S. Harrington, Smart Health Diagnostics Company (f/k/a
Predictive Health Diagnostics Company), and Matthew Nuñez.

GLASSCOCK, Vice Chancellor
      This matter alleges a rather breathtaking scheme to loot a Delaware entity.

According to the pleadings, Defendant Dr. Douglas Harrington founded Global

Discovery Biosciences with the financial backing of Dr. Khalid bin Jabor Al Thani

(“Dr. Khalid”). The purpose of the company was to monetize a testing procedure,

the PULS, which could identify early heart disease in patients. Briefly, a dispute

arose between Dr. Harrington, and entities and individuals associated with him, on

the one hand, and Dr. Khalid and his allies, as to who owned the controlling interest

in Global. When it became clear that the Harrington parties were going to lose that

battle, Dr. Harrington used his control of Global to transfer assets, including the

PULS technology and other assets and funds, to other entities within Dr.

Harrington’s control. He then caused Global to declare bankruptcy. The Khalid

faction, who in fact held the majority of Global equity, has assumed control of

Global, and had the bankruptcy petition discharged. Global now seeks to hold Dr.

Harrington and the other Defendants liable for theft of the PULS technology under

the Delaware Uniform Trade Secrets Act, and alleges a host of equitable and

common law torts against the Defendants as well, notably including breach of

fiduciary duty and conversion against Harrington.

      Before me is a partial motion to dismiss. The Defendants have moved to

dismiss causes of action in the complaint, generally, on two theories—that individual

causes of action, including under DUTSA, fail to state a claim; and that (assuming

                                         1
the DUTSA claim survives) that DUTSA preempts all or part of the remaining

common law claims. Following oral argument on the motion to dismiss, I found that

the DUTSA claim was sufficiently pled, and that the partial preemption argument

must be denied without prejudice, with respect to Counts I, II, V, and VI.1 I also

asked for, and received, supplemental briefing on whether the decisions of the

bankruptcy court should collaterally estop a count in the Complaint alleging the

Harrington and another Global fiduciary had breached fiduciary duties by placing

Global in bankruptcy.

       What follows is my decision on the balance of the Motion to Dismiss.

                                    I. BACKGROUND2

       A. Factual Background

              1. The Parties

       Plaintiff Global Discovery Biosciences Corporation (“Global” or the

“Company”) is a Delaware corporation and is a private biotechnology and medical

testing company, which was established in 2014 to develop and commercialize the

PULS Cardiac Test (the “PULS”).3

1
  Count I: Breach of Fiduciary Duty of Loyalty, Count II: Aiding and Abetting Breach of Fiduciary
Duty, Count V: Conversion, and Count VI: Unjust Enrichment.
2
  This memorandum opinion contains a brief recitation of facts and includes only those necessary
to my analysis.
3
  Am. Verified Compl. ¶ 5, Dkt. No. 28. (“Compl.”)

                                               2
        Defendant Dr. Harrington founded Global and previously served as the

chairman of its board of directors and President and CEO of the Company.4

        Defendant The Ark Partner LLC (“ARK”) is a Delaware limited liability

company owned and controlled by Dr. Harrington.5

        Defendant Smart Health Diagnostics Company (“Smart Health” or

“Predictive Health”), formerly known as Predictive Health, is a Delaware

corporation.6 It is also controlled by Harrington.

        Defendant Matthew Nuñez is a former Global CEO and currently serves as

the CEO of Smart Health, which is a position he held while serving as Global’s

CEO.7

        Defendant Daniel Angress is a former director and CEO of Global.8

        Defendant Visionary Private Equity Group (“VPEG”) is believed to be a

Missouri limited partnership.9

        Non-party Dr. Khalid bin Jabor Al Thani is an investor and stockholder of

Global.10

4
  Id. ¶ 6.
5
  Id. ¶ 7.
6
  Id. ¶¶ 8, 70.
7
  Id. ¶ 9.
8
  Id. ¶ 10.
9
  Id. ¶ 11.
10
   Id. ¶ 12.

                                          3
        Non-party Trivalley Trading & Contracting WLL (“Trivalley”) is Khalid’s

investment company, which Khalid used to invest in Global.11 Trivalley is also a

stockholder of Global.12

        Non-party Estrella Harrington, now deceased, was Harrington’s wife and

former director of Global.13

        Non-party Munira Al-Delemi was a former director of Global.14

                2. Global’s Formation and Harrington’s Representations Regarding
                Global’s Assets

        In April 2014, Khalid, through his investment company, Trivalley, provided

the seed investment in Global after being pitched by Harrington, which resulted in

Global’s formation.15 Khalid’s capital was used to commercialize Global’s product,

the PULS.16

        After Khalid’s investment, Harrington began to make representations to

investors, the public, and third parties that Global was the creator and sole owner of

the PULS; these representations spanned a period from 2014 to 2016.17

11
   Id.
12
   Id.
13
   Id. ¶¶ 27, 33.
14
   Id. ¶ 48.
15
   Id. ¶ 12.
16
   Id.
17
   Id. ¶¶ 13–19.

                                          4
               3. Dr. Harrington Disputes Khalid’s Stock Ownership

       On September 21, 2016, Khalid and Trivalley sent Global a letter requesting

to inspect Global’s books and records, after Khalid’s questions concerning Global’s

state of business affairs had gone unanswered.18 Harrington directed Global to deny

the request, asserting that Khalid and Trivalley were never stockholders of Global.19

After denying the inspection demand, Harrington caused Global to file a lawsuit in

California challenging Khalid’s and Trivalley’s stock ownership.20

       In that action, the California court ruled that Harrington’s challenge to

Khalid’s and Trivalley’s stock ownership was meritless, finding that Khalid and

Trivalley were entitled to a 55% ownership interest in the total number of shares of

Global.21 Consequently, Khalid and Trivalley moved for summary adjudication.22

On March 11, 2021, however, before the matter was decided, Global’s counsel

informed the court and opposing counsel that Global had filed for bankruptcy.23 As

a result, the hearing was vacated, and the court in the California litigation entered a

stay of proceedings pending the bankruptcy.24

18
   Id. ¶ 19.
19
   Id.
20
   Id. ¶ 20; Global Discovery Biosciences Corp. v. Khalid bin Jabor Al Thani, et al., No. 30-2016-
00878822-CU-BC-WJC (Cal. Super. Ct. Nov. 18, 2019) (“Cal. Litigation”).
21
   Compl. ¶ 21; Cal. Litigation.
22
   Id. ¶ 22.
23
   Id. ¶ 23.
24
   Id.

                                                5
               4. Dr. Harrington Forms Smart Health and Transfers Global’s Assets

       Thereafter, Harrington formed Predictive Health—now Smart Health—on

November 22, 2016.25 Harrington was and is Predictive Health’s founder and

controlling stockholder, and serves as its chairman.26 After forming Predictive

Health, Harrington transferred Global’s assets and intellectual property, which

included the PULS, the laboratory Global operated from, its laboratory equipment,

and its laboratory personnel to Predictive Health.27

       Further, Harrington caused Global to enter one-sided contracts with Predictive

Health that diverted all of Global’s revenue to Predictive Health.28 In addition,

Harrington attempted to convert Global into a licensee of Predictive Health.29

Specifically, Global entered into a license agreement for the PULS with Predictive

Health that would renew every year and require Global to pay Predictive Health a

yearly license fee of $25,000, plus $25 per Cardiac PULS Test result.30 Thereafter,

Dr. Harrington rebranded PULS as the Predictive Health Diagnostics PULS Cardiac

Test.31

25
   Id. ¶ 24.
26
   Id.
27
   Id. ¶ 25. That is, the former Global employees became Predictive Health employees. In addition,
Smart Health uses the same business address as Global. Id. ¶ 24.
28
   Id.
29
   Id.
30
   Id.
31
   Id. ¶ 26.

                                                6
       All of Global’s internal decisions were made by Harrington and his wife,

Estrella Harrington, who held two out of three board seats on Global’s board.32 The

two made numerous corporate decisions without observing corporate formalities.33

       Around August 2017, Harrington accepted an investment from VPEG, which

appeared to involve the purchase of a controlling interest in Predictive Health, as

VPEG publicly describes Smart Health f/k/a Predictive Health as one of its portfolio

companies.34 This transaction was not made known to Global stockholders.35

VPEG’s investment allowed Predictive Health to commercialize the PULS, from

which VPEG in turn received profits.36

       At a certain time, Harrington, as CEO of Global and majority stockholder of

Predictive Health, drafted and executed another agreement between the companies.37

The new agreement terminated Global’s license agreement and replaced it with

another license agreement, which was to be renewed monthly.38 Neither Khalid nor

Trivalley were informed of either license agreement.39 During this time period,

Harrington, as Chairman of Global and majority stockholder of Predictive Health,

32
   Id. ¶ 27.
33
   Id. Dr. Harrington and Ms. Harrington failed to hold meetings, provide notice to the other
director of Global, provide notice to stockholders, create a written record of board actions, and
take minutes of meetings. Id.
34
   Id. ¶ 29.
35
   Id.
36
   Id.
37
   Id. ¶ 32.
38
   Id.
39
   Id.

                                               7
and Mr. Nuñez, as CEO of both Global and Predictive Health, transferred millions

of dollars in assets from Global to Predictive Health.40

       On April 7, 2020, Harrington created a new medical laboratory named

Morningstar Laboratories, LLC (“Morningstar”), with the goal of transferring all of

Global’s remaining assets to Morningstar.41 Harrington transferred Global’s lease

of its facilities to Predictive Health and caused Global to enter into a “services

contract,” where Global would continue to pay the rent and Predictive Health would

enjoy the premises for free.42 Afterwards, Harrington and Nuñez started transferring

contracts for Cardiac PULS Tests from Global to Morningstar.43 The pair also

transferred all of Global’s laboratory equipment to Predictive Health, and left the

equipment leases in Global’s name.44 In addition, Harrington and Nuñez transferred

all of Global’s employees to Predictive Health.45 Subsequently, Predictive Health

began developing other tests utilizing Global’s assets, laboratory space, and

employees.46

40
   Id. ¶ 34. In addition, Dr. Harrington and Mr. Nunez caused Global to transfer income to
Predictive Health and then caused Global to take out loans to pay its bills and meet its expenses
before transferring all of Global employees to Predictive Health. Id. ¶ 40.
41
   Id. ¶ 35. Morningstar’s address was listed as Global’s address. Id.
42
   Id. Global formally leased the space in 2014 on a three-year term with option to renew. Id.
43
   Id. ¶ 36.
44
   Id. ¶ 37. Global continued to be billed and paid taxes on the equipment. Id.
45
   Id. ¶ 38. Global entered into a contract with Morningstar to continue paying salaries of the
employees despite Predictive Health being the actual employer. Id. Global remained responsible
for 80% of the rent. Id.
46
   Id. ¶ 39.

                                               8
               5. Dr. Khalid and Trivalley Demand to Inspect Global’s Books and
               Record and Remove Global’s Board of Directors

       On November 13, 2020, Khalid and Trivalley made another attempt to inspect

Global’s books and records by making a formal demand to the Company.47

Harrington caused Global to reject their demand.48 Soon after, on November 25,

2020, Khalid and Trivalley filed an action under Section 220 to enforce their

inspection rights.49 Then, on February 12, 2021, Khalid and Trivalley served written

consent of the holders of a majority of outstanding stock of Global, removing all the

directors of Global and appointing four new directors (the “New Directors”).50

Khalid and Trivalley filed an action in this Court under Section 225 to confirm the

validity of the consent, which I ultimately found valid.51

               6. Global Files a Bankruptcy Action

       Harrington, acting as owner of ARK, appointed Angress as director and CEO

of Global.52 On March 11, 2021, Harrington caused Global to file a bankruptcy

petition not authorized by the New Directors, which was filed after the Harringtons

47
   Id. ¶ 42.
48
   Id.
49
   Id. Global did not produce a document in response to the Section 220 demand. Id.
50
   Id. ¶ 43.
51
   Id. ¶ 69; In re Glob. Discovery Biosciences Corp., 2022 WL 1744017, at *7 (Del. Ch. May 31,
2022). I also confirmed that Dr. Khalid and Trivalley held a 55% ownership in Global. Id.
52
   Compl. ¶ 49. Burke, Angress, and Harrington were the only ones present for this resolution. Id.
On May 19, 2021, the bankruptcy court entered an order granting in part Khalid’s motion to
dismiss.

                                                9
had been removed from the Global board.53 On April 19, 2021, Angress attempted

to ratify the board’s resolution authorizing Global’s bankruptcy petition by a written

consent signed by himself and Ms. Al-Delemi.54

        The schedules and statements which were filed in bankruptcy court revealed

Predictive Health was the largest unsecured creditor of Global’s bankruptcy estate,

which amounted to $1.5 million.55        It further revealed that the Harringtons

unlawfully transferred intellectual property from Global to Predictive Health at some

point after Harrington filed suit against Khalid over his ownership of Global.56

Thereafter, on August 24, 2022, Predictive Health filed an Amended and Restated

Certificate of Incorporation with the Delaware of Secretary of State formally

changing the company’s name from Predictive Health to Smart Health.57 On

October 31, 2022, the bankruptcy court dismissed the bankruptcy action pursuant to

Khalid’s and Trivalley’s motion to dismiss, which gave control to the New

Directors.58

53
   Id. ¶ 51.
54
   Id. ¶ 54.
55
   Id. ¶ 55.
56
   Id. ¶ 61.
57
   Id. ¶ 70.
58
   Id. ¶ 72.

                                         10
       B. Procedural History

       Plaintiff filed its original Complaint on December 7, 2022, and later filed an

amended complaint (the “Amended Complaint”) on April 13, 2023.59 The Amended

Complaint asserts causes of action against Harrington, ARK, Smart Health, Nuñez,

Angress, and VPEG.60 Thereafter, Defendants moved to dismiss the Amended

Complaint for failure to state a claim on April 27, 2023.61 I heard oral argument on

Defendants’ Motion to Dismiss on August 17, 2023, where I provided a bench

ruling.62

       In the bench ruling, I denied Defendants’ motion to dismiss with respect to

Count I (Breach of Fiduciary Duty), Count II (Aiding and Abetting Breach of

Fiduciary Duty), Count V (Conversion), and Count VIII (Misappropriation of Trade

Secrets Under Uniform Trade Secrets Act) without prejudice to Defendants’ ability

to argue that the Delaware Uniform Trade Secrets Act (“DUTSA”) partially

preempts the common-law counts.63               I directed the parties to submit brief

supplemental memorandum regarding the basis of the bankruptcy court’s

59
   Verified Compl., Dkt. No. 1; Compl.
60
   Compl. ¶¶ 32–148.
61
   Defs.’ Mot. to Dismiss Pl.'s Am. Verified Compl., Dkt. No. 34. VPEG and Angress were not a
part of the joint filing. See id. In addition, VPEG and Angress have not entered an appearance in
this action. I issued a Rule to Show Cause as to VPEG and Angress. See Memo. to Register in
Chancery to Show Cause, Dkt. No. 56. The parties did not respond, and I entered default judgment
against them at oral arguments on the motion to dismiss. Oral Arg. Tr. 65:17– 69:16, Dkt. No. 62.
62
   Letter Op., Dkt. No. 66.
63
   Id.

                                               11
consideration of the bad faith of Global’s bankruptcy filing.64 On August 23, 2023,

the parties entered their supplemental memorandum, and I considered the matter

submitted as of that date.65

       This Memorandum Opinion addresses the remaining counts of Defendants’

motion to dismiss for failure to state a claim.

                                       II. ANALYSIS

       Defendants have moved to dismiss the claims under Court of Chancery Rule

12(b)(6). When reviewing such a motion,

       (i) all well-pleaded factual allegations are accepted as true; (ii) even
       vague allegations are well-pleaded if they give the opposing party
       notice of the claim; (iii) the Court must draw all reasonable inferences
       in favor of the non-moving party; and (iv) dismissal is inappropriate
       unless the plaintiff would not be entitled to recover under any
       reasonably conceivable set of circumstances susceptible of proof.66

I need not, however, “accept conclusory allegations unsupported by specific facts or

... draw unreasonable inferences in favor of the non-moving party.”67 In addition, I

refer to certain documents that are incorporated by reference in the Amended

Complaint.68

64
   Id.
65
   Defs.’ Suppl. Mem. in Supp. of Defs.’ Mot. to Dismiss Pl.’s Am. Compl., Dkt. No. 68; Letter in
Response to Directive at Oral Arg. Requesting Suppl. Mem., Dkt. No. 69.
66
   Savor, Inc. v. FMR Corp., 812 A.2d 894, 896–97 (Del. 2002) (footnotes omitted) (internal
quotations omitted).
67
    Windsor I, LLC v. CWCapital Asset Mgmt. LLC, 238 A.3d 863, 871 (Del. 2020) (citation
omitted).
68
   Id. at 873 (quoting Vanderbilt Income & Growth Assoc., LLC v. Arvida/JMB Managers, Inc.,
691 A.2d 609, 613 (Del. 1996)).

                                               12
       A. Count III: Fraud Against Smart Health and ARK

       Plaintiff asserts a fraud claim against Smart Health and ARK alleging that

Smart Health falsely claimed that it was the owner of Global’s assets while

purportedly knowing that the assets had been wrongfully transferred from Global,

and that Smart Health “misle[d]” Global into entering a licensing agreement on the

basis that Smart Health owns the PULS.69 Defendants argue in part that it is a “legal

impossibility” that Harrington, as key executive on both sides of the licensing

transaction between Global and Smart Health, created a falsification of ownership

and tricked himself with that falsification.70 I agree.

       To state a fraud claim, the plaintiff must plead facts supporting an inference

that: “(1) the defendant falsely represented or omitted facts that the defendant had a

duty to disclose; (2) the defendant knew or believed that the representation was false

or made the representation with a reckless indifference to the truth; (3) the defendant

intended to induce the plaintiff to act or refrain from acting; (4) the plaintiff acted in

justifiable reliance on the representation; and (5) the plaintiff was injured by its

reliance.”71 Factors three and four are lacking here.

69
   Compl. ¶¶ 96–99.
70
   Defendants also argue that this count is preempted by DUTSA, 6 Del. C. § 2001. Opening Br.
of Defs. in support of their Mot. to Dismiss Pl.’s Am. Compl. 34–38, Dkt. No. 42 (“DF OB”).
Since the fraud claim fails to state a claim, I decline to address whether the fraud claim is
preempted by DUTSA.
71
   DCV Holdings, Inc. v. Conagra, Inc., 889 A.2d 954, 958 (Del. 2005).

                                             13
       The Amended Complaint fails to state a claim for fraud pertaining to

Harrington’s actions in causing Global to enter the licensing agreement because

Plaintiff cannot successfully allege that Harrington intended to induce himself to act

or refrain from acting. Plaintiff argues that Defendants’ proposition of a “legal

impossibility” ignores the fact that Smart Health and Global are separate entities.72

Yet Plaintiff’s position is itself anomalous: it essentially states that a corporation’s

controller acted to defraud himself.73 Put another way, Global, through its controller

Harrington, was aware of the true state of affairs, and cannot have been misled by

any false statements of fact that Harrington caused Smart Health to make. Global

was acting only through Harrington. Plaintiff’s circular reasoning is inadequate to

convey an intention of Harrington to induce himself to act or refrain from acting on

behalf of Global, or reasonable reliance thereon, as required to support a fraud claim.

       In connection with the fraud claim, Global also contends that Harrington and

ARK “defrauded” Global by causing repayment of certain loans to ARK.74 I confess

that I do not understand how this states a claim for fraud, although the repayment of

the loans may be otherwise actionable.

       Accordingly, Defendants’ motion to dismiss Count III is granted.

72
   Pl.'s Answering Br. in Opp’n to Defs.' Mot. to Dismiss Am. Compl. 42–45, Dkt. No. 52 (“PL
AB”).
73
   Id.
74
   Compl. ¶ 99.

                                            14
       B. Count IV: Civil Conspiracy Against Harrington, Nuñez, ARK, Smart and
       Health

       Plaintiff contends that Harrington, Nuñez, Smart Health, and ARK

orchestrated a civil conspiracy by entering into a combination or confederation for

purposes of misappropriating Global’s assets so they, not Global stockholders,

would receive revenue from those assets.75               Plaintiff further asserts that in

furtherance of the conspiracy, Harrington, Nuñez, Smart Health, and ARK used their

positions at Global and Smart Health to access Global’s documents to facilitate

transferring Global’s assets to Smart Health.76

       To assert a claim for civil conspiracy, a plaintiff must allege: “(1) two or more

persons; (2) an object to be accomplished; (3) a meeting of the minds . . .relating to

the object or . . .course of action; (4) one or more unlawful acts; and (5) damages as

a proximate result thereof.”77 However, a corporation cannot be deemed to have

conspired with its officers and agents since “it cannot conspire with itself any more

than a private individual can, and it is the general rule that the acts of the agent are

the acts of the corporation.”78

75
   Compl. ¶ 101.
76
   Id. ¶ 102.
77
   See Metro. Life Ins. Co. v. Tremont Grp. Hldgs., Inc., 2012 WL 6632681, at *19 (Del. Ch. Dec.
20, 2012) (quoting Matthew v. Laudamiel, 2012 WL 605589, at *8 (Del. Ch. Feb. 21, 2012)).
78
   In re Transamerica Airlines, Inc., 2006 WL 587846, at *6 (Del. Ch. Feb. 28, 2006); Nelson
Radio & Supply Co. v. Motorola, Inc., 200 F.2d 911, 914 (5th Cir. 1952).

                                              15
       Defendants argue that Plaintiff has not articulated a factual basis for including

VPEG or ARK in the conspiracy claim, since Plaintiff has not alleged with

specificity that VPEG or ARK participated in the transfer of the PULS to Smart

Health.79 Thus, in Defendants’ view, only Smart Health and its agents are left as

potential conspirators, and these agents and their principal cannot conspire with

themselves.80 However, at this pleading stage, it is sufficient that Harrington’s

knowledge is conceivably imputed to ARK; moreover, VPEG has defaulted with

respect to the allegations of the Amended Complaint. Given the plaintiff-friendly

standards here, the Amended Complaint adequately states a claim of conspiracy to

convert Global’s assets against these Defendants.

       Accordingly, Defendants’ motion to dismiss Count IV is denied.

       C. Count VII: Tortious Interference Against Smart Health

       Plaintiff argues that Smart Health interfered with Global’s ability to form

business relationships and Global’s existing contracts related to the PULS by

usurping the PULS and advertising itself as the owner of the PULS.81 Plaintiff

further asserts that VPEG participated in Smart Health’s interference by funding

Smart Health’s efforts.82 Defendants argue in part that Plaintiff has failed to identify

79
   DF OB 38–41.
80
   Id.
81
   Compl. ¶ 118.
82
   Id. ¶ 119.

                                          16
a breach with existing contracts and further failed to assert with particularity the

prospective contracts.83 I agree with Defendants.

              1. Tortious Interference with Contract

       To assert a claim for tortious inference of a contract, a plaintiff must establish

there is “(1) a contract, (2) about which defendant knew and (3) an intentional act

that is a significant factor in causing the breach of such contract (4) without

justification (5) which causes injury.”84

       Plaintiff fails to allege that a breach of contract occurred with respect to the

LifeLabs and CHL contracts, the only contracts that the Amended Complaint

expressly mentions.85 Plaintiff asserts that the Amended Complaint alleges, in

conclusory fashion, Defendants’ interference with its contracts, however, this is

insufficient to survive at the motion to dismiss stage, since Plaintiff must also allege

a breach in respect to those contracts.86 As such, I find that Plaintiff fails to plead a

prima facie claim for tortious interference with contract since Plaintiff does not

allege a breach of either the LifeLabs nor CHL (or other) contracts.

       I note that the Amended Complaint alleges that the Defendants wrongfully

assigned or transferred contracts from Global to Morningstar; that does not, in my

83
   DF OB 45–47. Defendants also argue that DUTSA preempts Plaintiff’s claim. Id. 25–26.
84
   Irwin & Leighton, Inc. v. W.M. Anderson Co., 532 A.2d 983, 992 (Del. Ch. 1987) (citations
omitted).
85
   See Compl. ¶¶ 116–120.
86
   PL AB 51; Irwin & Leighton, Inc. v. W.M. Anderson Co., 532 A.2d 983, 992 (Del. Ch. 1987).

                                            17
view, state a claim for tortious interference. However, those allegations, if proved,

are remediable in damages under other causes of action pled in the Amended

Complaint.

              2. Tortious Interference with Prospective Business Relations

       To establish a claim for tortious interference with prospective business

relations, a plaintiff must establish “(1) the reasonable probability of a business

opportunity, (2) the intentional interference by defendant with that opportunity, (3)

proximate causation, and (4) damages, all of which must be considered in light of a

defendant's privilege to compete or protect his business interests in a fair and lawful

manner.”87 Further, “to plead a reasonable probability of a business opportunity, [a

plaintiff] must identify a specific party who was prepared to enter into a business

relationship but was dissuaded from doing so by the defendant and cannot rely on

generalized allegations of harm.”88

       Plaintiff fails to allege a reasonable probability of a business opportunity.

Plaintiff asserts that its lost business opportunities are the commercialization of the

PULS and the additional medical tests that Plaintiff could have developed had

Defendants not converted Plaintiff’s assets.89 However, nowhere in the Amended

87
   DeBonaventura v. Nationwide Mut. Ins. Co., 419 A.2d 942, 947 (Del. Ch. 1980).
88
   Organovo Hldgs, Inc. v. Dimitrov, 162 A.3d 102, 122 (Del. Ch. 2017) (quoting Agilent Techs.,
Inc. v. Kirkland, 2009 WL 119865, at *7 (Del. Ch. Jan. 20, 2009) (internal quotations omitted)).
89
   PL AB 51; Comp ¶¶ 140, 142. The assets referred to include intellectual property, laboratory
space, equipment, and employees.

                                              18
Complaint does Plaintiff assert potential contracts or opportunities that Defendants

interfered with.90 Plaintiff instead gives conclusory statements that Defendants

thwarted Plaintiffs’ business opportunities, all of which are insufficient to survive at

the motion to dismiss stage.91 Therefore, I find that Plaintiff fails to plead a prima

facie claim for tortious interference with prospective business relations. Again, the

allegations here may support a recovery under other theories pled in the Amended

Complaint.

       Accordingly, Defendants’ motion to dismiss Count VII is granted.

       D. Count X: Breach of Fiduciary Duty – Bankruptcy Against Harrington

       Plaintiff contends Harrington, as a former director of Global, owed fiduciary

duties to the Company and asserts that Harrington appointed Angress as director of

Global to place the Company into bankruptcy.92 Plaintiff asserts that Harrington

breached his fiduciary duties by unlawfully causing Global to file for bankruptcy to

avoid judgment in corresponding litigation.93 Plaintiff alleges it was harmed by

Harrington’s actions and has no adequate remedy at law.94 Defendants argue that

the Bankruptcy Code preempts Plaintiff’s claim and that because the parties already

90
   See Compl. ¶¶ 116–120.
91
   See Enzo Life Scis., Inc. v. Digene Corp., 295 F.Supp.2d 424, 429 (D. Del. 2003) (surviving
motion to dismiss stage where plaintiff identified a business prospect by pointing to potential
customers who were dissuaded from buying a product).
92
   Compl. ¶ 135.
93
   Id. ¶ 136.
94
   Id. ¶¶ 137–38.

                                              19
litigated whether the bankruptcy filing was in bad faith, collateral estoppel bars

Plaintiff’s claim as well.95

       The Article VI doctrine, known as the Supremacy Clause, requires a state

action be declared unenforceable where valid federal legislation preempts state

authority.96 In determining whether state law is preempted, courts look to whether

there is express preemption, field preemption, or conflict preemption in the area.97

Defendants argue that claims based on bad faith filings are preempted here, because

the Bankruptcy Code preempts state law tort claims in the entire field of

bankruptcy.98 Title 11 gives federal courts original and exclusive jurisdiction of all

cases under it, that is, cases in bankruptcy.99 Further, Title 11 contains remedies and

penalties for the exploitation of its process, presumably including bad-faith abuse of

process.100 Federal authority, however, appears split on whether abuse of process in

regard to an improper bankruptcy filing is preempted, or whether a state court can

entertain an analogous claim.101 At this plaintiff-friendly stage, the record should be

95
   DF OB 48–50.
96
   See Blum v. Bacon, 457 U.S. 132 (1982).
97
   Farina v. Nokia Inc., 625 F.3d 97, 115 (3d Cir. 2010) (quoting Hillsborough Cnty. v. Automated
Med. Labs., Inc., 471 U.S. 707, 713 (1985)).
98
   DF OB 48–50.
99
   28 U.S.C. § 1334.
100
    See 11 U.S.C. § 303(i)(2) (individuals who file involuntary bankruptcy petitions in bad faith
are liable for damages); 11 U.S.C. § 362(h) (individuals who willfully violate bankruptcy stays are
liable for damages); Astor Holdings, Inc. v. Roski, 325 F. Supp. 2d 251, 262 (S.D.N.Y. 2003).
101
    See Kecki v. Texas Enters., LLC, 2021 WL 3237134, at *3 (Del. Ch. July 30, 2021) (citing
Nelson v. Emerson, 2008 WL 1961150, at *8 n.51 (Del. Ch. May 6, 2008)); In re Bral, 622 B.R.
737, 744–47 (9th Cir. 2020); Rosenberg v. DVI Receivables XVII, LLC, 835 F.3d 414 (3d Cir.
2016); Robbins v. Fulton Bank, N.A., 2018 WL 1693386 (E.D. Pa. Apr. 6, 2018)).

                                                20
further developed to assist in determining whether Count X is preempted by the

Bankruptcy Code, thus Defendants’ motion to dismiss relating to this claim is denied

on that basis without prejudice to further motion practice upon a record.

       I now turn to Defendants’ alternative argument of collateral estoppel. The

doctrine of collateral estoppel states that “when an issue of ultimate fact has once

been determined by a valid and final judgment, that issue cannot again be litigated

between the same parties in any future lawsuit.”102 To trigger collateral estoppel,

each of the following four factors must be present: “‘(1) the issue previously decided

is identical with the one presented in the action in question, (2) the prior action has

been finally adjudicated on the merits, (3) the party against whom the doctrine is

invoked was a party or in privity with a party to the prior adjudication, and (4) the

party against whom the doctrine is raised had a full and fair opportunity to litigate

the issue in the prior action.””103

       Defendants argue that Count X is barred by collateral estoppel since the

parties litigated the issue of bad faith and the bankruptcy court denied relief

stemming from the claim that the bankruptcy petition was filed in bad faith.104 I

disagree. The issue previously litigated has not been adjudicated on the merits. It is

102
    Norman v. State, 976 A.2d 843, 868 (Del. 2009) (citing Ashe v. Swenson, 397 U.S. 436, 443
(1970)).
103
    Id. (citing Capano v. State, 889 A.2d 968, 986 (Del.2006) (Steele, C.J. dissenting)); Betts v.
Townsends, Inc., 765 A.2d 531, 535 (Del.2000); see also 18 JAMES WM. MOORE ET AL.,
MOORE'S FEDERAL PRACTICE §§ 132–1, 132.04[1][a][ii] (3d ed. 1997)).
104
    DF OB 50.

                                               21
true that the bankruptcy court initially denied dismissal based on a theory that the

filing had been made in bad faith, and declined to award fees for bad faith pursuant

to Section 9011 of the Federal Rules of Bankruptcy Procedure.105 This ruling,

however, was predicated on the ongoing litigation in this Court while it determined

ownership and control of Global.106 This is made clear in the bankruptcy court’s

final adjudication dismissing the action after determining that Global did not possess

corporate authority in the filing of its bankruptcy petition.107 Also, the order

explicitly mentioned that Plaintiff was not foreclosed from pursuing an appropriate

motion for sanctions or state law claims.108 Plaintiff’s claim seeking relief for a bad

faith filing is not barred through issue preclusion (although, as explained above, still

unresolved is whether the claim is preempted).

       Accordingly, Defendants’ motion to dismiss Count X is denied.

       E. Count XI: Usurpation of Corporate Opportunity Against Harrington and
       Nuñez

       Plaintiff asserts that Smart Health is developing other medical tests, which

Global could have developed if Global still had use of its laboratory space,

105
    DF OB Ex. C.; DF OB Ex. F; DF OB 51.
106
    DF OB Ex. C, at 2. “The Court will abstain under Section 1334, Title 28, of the United States
Code from adjudicating the disputes among the shareholders or purported shareholders of the
Debtor regarding the ownership and control of the Debtor and will allow such disputes to be
resolved in connection with the proceedings already pending before the Delaware Chancery Court.
. .” Id.
107
    Compl. Ex. C, at 2.
108
    Id. at 5.

                                               22
equipment, and employees, amounting to an improper usurpation of Global’s

opportunity.109 Plaintiff contends that these medical tests were in Global’s line of

business.110 Plaintiff argues that it has been damaged as a result of Defendants’

breach of fiduciary duties and there is no adequate remedy at law.111 Defendants

contend that Global has not offered sufficient facts to support that Global had an

opportunity to expand into creating additional medical tests, nor Global’s financial

ability to exploit such opportunity.112 Plaintiff, in turn, points out that the nature of

a corporation’s business should be broadly interpreted and that it would have had

the financial means to pursue the opportunity had Defendants not looted the

Company, and was in a position to fund expansion through borrowing.113

       The elements of misappropriation of corporate opportunity are: (1) an

opportunity within the corporation's line of business; (2) the corporation’s interest

or expectancy in the opportunity; that (3) the corporation was financially able to

exploit the opportunity; and that (4) by taking the opportunity for his own, the

corporate fiduciary is placed in a position inimical to his duties to the corporation.114

109
    Compl. ¶¶ 140–42.
110
    Id. ¶ 143.
111
    Id. ¶¶ 147–48.
112
    DF OB 54–57.
113
    PL AB 57–59.
114
    McGowan v. Ferro, 859 A.2d 1012, 1038 (Del. Ch. 2004), j. entered sub nom. McGowan v.
Ferro, Jr. (Del. Ch. 2004), aff'd sub nom. McGowan v. Ferro, 873 A.2d 1099 (Del. 2005), and
aff'd sub nom. McGowan v. Ferro, 873 A.2d 1099 (Del. 2005) (citing Broz v. Cellular Info. Sys.,
Inc., 673 A.2d 148, 154–55 (Del.1996)).

                                              23
       Plaintiff has sufficiently alleged a prima facie claim for usurpation of a

corporate opportunity. First, a corporation’s line of business is interpreted broadly

for purposes of a misappropriation analysis, and here, where Plaintiff receives

favorable inferences pursuant to Rule 12(b)(6), Plaintiff has satisfied the first prong

of the test by stating its line of business is the development of medical tests.115

Second, Plaintiff sufficiently states it had an interest in developing additional

medical tests, by pointing to Harrington and Nunez who, as fiduciaries of Global,

diverted the opportunity to Smart Health.116 Third, Plaintiff also asserts that it had

the financial means to exploit the opportunity by stating that it could have raised

funds to do so.117 Finally, Plaintiff adequately states that Harrington, as the creator

of Smart Health and a fiduciary of Global, took a position adverse to the interests of

Global.118

       It is true that Plaintiff’s overall basis for litigation is seeking a remedy for the

exploitation of its assets. Plaintiff alleges that Defendants looted virtually all of its

assets.    As I understand Defendants’ argument, they point to this as rebutting

Global’s claim of financial ability to exploit the opportunities which Defendants are

now pursuing. I can credit the Defendants, at least, with chutzpah in arguing that,

115
    Compl. ¶ 143; see Dweck v. Nasser, 2012 WL 161590, at *13 (Del. Ch. Jan. 18, 2012); see also
Pers. Touch Hldg. Corp. v. Glaubach, 2019 WL 937180, at *16 (Del. Ch. Feb. 25, 2019).
116
    Compl. ¶ 144.
117
    Id. ¶ 142.
118
    Id. ¶ 145.

                                              24
having allegedly looted Global, Defendants deprived Plaintiff of the ability to

demonstrate an element of the tort. Nevertheless, at the 12(b)(6) stage, where

favorable inferences are given to Plaintiff, I find the allegations sufficient to survive

a motion to dismiss. Additionally, in the context of a record to be created, I may

assess how equity should view the financial ability element of the tort, in light of the

Company allegedly having been looted by the tortfeasors.

      Accordingly, Defendants’ motion to Dismiss Count XI is denied.

                                 III. CONCLUSION

      The gravamen of this action is the wrongful conversion of assets from Global

by its fiduciaries. Ample legal remedies are available for the full redress of those

wrongs, if proven. Some of the Plaintiff’s more tangential theories, however, fail to

state claims.

      For the foregoing reasons, the Defendants’ motion to dismiss the Amended

Complaint is GRANTED and DENIED in part. The parties should submit a form of

order consistent with this Memorandum Opinion.

                                           25